The Cholesterol War Is Over (Here's Who Won)

In 2006, researchers in Dallas found a woman who broke everything we thought we knew about cholesterol.

She was 32 years old. A healthy aerobics instructor. Normal liver, normal kidneys, no health problems. But when they tested her blood, her LDL cholesterol came back at 14.

Not 140. Fourteen.

To put that in perspective, the average LDL cholesterol in a healthy adult is around 100 to 130 mg/dL. Doctors start getting concerned above 160. Below 70 is considered excellent for high-risk patients. US guidelines have most recently set the target at less than 55 mg/dL for secondary prevention, and less than 70 mg/dL for high-risk primary prevention with diabetes [1]. This woman was at 14. How was that possible?

Table of Contents

• The Woman With No PCSK9
• How PCSK9 Works — and the Drug It Inspired
• From Number to Outcome: FOURIER and VESALIUS-CV
• The Diabetes Subgroup — ACC 2026
• Ez-PAVE: The First LDL Target Trial
• The Drug Almost Nobody Is Using
• References

The Woman With No PCSK9

Helen Hobbs wanted to find out. The irony is, she hadn't planned on studying cholesterol. When her mentor at UT Southwestern suggested she join a lipid research lab, her reaction was immediate: "Lipoproteins. Oh, no. So boring." As she later admitted: "That just tells you how little I understood about science." [2]

She and Jonathan Cohen had been running a massive project called the Dallas Heart Study — collecting DNA from thousands of residents and linking it to their medical records to see what patterns emerged.

In some people, they noticed astonishingly low LDL cholesterol levels. When they checked the DNA, they found mutations in a gene called PCSK9. But these mutations weren't making the gene overactive. They were shutting it down.

And the people who carried these mutations weren't sick. They were thriving. They had dramatically lower rates of heart disease — an 88% reduction in coronary heart disease risk [3].

That aerobics instructor? She had mutations in both copies of PCSK9. Her body produced none of the protein. And she was perfectly healthy.

What Hobbs had stumbled onto was the clearest natural experiment in cardiovascular medicine. If you could block PCSK9, you could dramatically lower LDL cholesterol — safely. The race to build a drug that could mimic what this woman's DNA did naturally had begun.

Hobbs later described how fast the field moved: "Geneticists took a little while to understand this, but the pharmaceutical companies got it right away." [2]

How PCSK9 Works — and the Drug It Inspired

In simple terms, PCSK9 destroys the receptors your liver uses to pull LDL particles out of your blood. The more PCSK9 you have, the fewer receptors survive, and the higher your cholesterol climbs. Block PCSK9, and those receptors survive — more cholesterol gets cleared [4].

Amgen designed a monoclonal antibody called evolocumab — a protein that latches onto circulating PCSK9 and neutralises it before it can destroy LDL receptors [5].

In early trials, LDL cholesterol dropped up to 81% on top of statin therapy. For patients who'd struggled with high cholesterol despite maximum statin doses, this was a completely new tool [5].

But lowering a number on a blood test isn't the same as preventing heart attacks. That required a much bigger, much longer, much more expensive study.

From Number to Outcome: FOURIER and VESALIUS-CV

The FOURIER trial was that study. Over 27,000 patients with existing heart disease. Half received evolocumab, half received placebo — all on top of statin therapy [6].

The result: a 20% reduction in heart attacks, strokes, and cardiovascular death [6].

That was a triumph. But it came with a caveat that critics were quick to point out. Every patient in FOURIER already had established heart disease. Sceptics argued that aggressive LDL-lowering might only help people who were already in trouble. Maybe pushing cholesterol that low in healthier patients would cause more harm than good.

The harder question was: what if you started earlier? Could you prevent the first heart attack — not just the second or third?

So in a follow-up study called the VESALIUS-CV trial, researchers looked at over 12,000 patients across 33 countries. None had ever had a heart attack or stroke. All had atherosclerosis or high-risk diabetes with LDL levels of at least 90 mg/dL [7].

After 4.6 years of follow-up — roughly twice as long as FOURIER — the answer came back: yes. A 25% reduction in heart attacks, strokes, and cardiovascular death [7].

It had taken twenty years, but what Helen Hobbs found in that aerobics instructor's blood had been validated on the largest scale imaginable. Ultra-low LDL wasn't dangerous. It was protective. And now we had proof that deliberately lowering it — before a heart attack ever happens — could prevent that heart attack from ever occurring.

But VESALIUS-CV included a mix of patients — some with existing atherosclerosis, some with diabetes but no visible disease. The question was whether the benefit held up in that second group. The ones furthest back in the disease process. The ones most doctors wouldn't think to treat aggressively.

The Diabetes Subgroup — ACC 2026

That question was answered on March 28th, 2026, at the American College of Cardiology conference in New Orleans.

Researchers presented a pre-specified analysis of just the diabetes patients in VESALIUS-CV — 3,655 people with diabetes who had never had a heart attack, never had a stroke, and had no known significant atherosclerosis [1].

Half received evolocumab. Half received placebo. They were followed for a median of 4.8 years [1].

At 48 weeks, LDL cholesterol in the treatment group dropped to 52 mg/dL, compared to 111 mg/dL in the placebo group. By 96 weeks, the median was down to 44 mg/dL — more in line with the 40 to 55 mg/dL target typically reserved for very high-risk secondary prevention [1].

And the clinical impact was striking.

The combination of heart attacks, strokes, and cardiovascular death was reduced by 31%. 5.0% in the evolocumab group versus 7.1% in the placebo group — a hazard ratio of 0.69 [1].

And then there was an exploratory finding that stopped me in my tracks: a signal for reduced all-cause mortality. There was a 24% lower risk of dying from any cause — the incidence of all-cause mortality was 7.36% in the evolocumab group and 9.52% in the placebo group [1].

Now, this is a subgroup analysis, and mortality wasn't a pre-specified outcome — so we can't make definitive claims. But a hazard ratio of 0.76 for all-cause mortality in a primary prevention population is a signal you take seriously.

One detail that matters: the benefit emerged after the first year. That's consistent with atherosclerosis prevention — the drug was stopping plaque from forming in the first place, not stabilising existing plaque. This wasn't a quick fix. It was a slow, steady accumulation of protection [1].

Dr Nicholas Marston, one of the study authors, put it directly: "I think this study changes the paradigm. We don't have to wait until someone has atherosclerosis to treat them intensively." [8]

It challenges the way most doctors think about cholesterol treatment — waiting for the disease to declare itself before getting aggressive. This data suggests that waiting costs lives.

But here's the problem. Evolocumab is an injection. It costs thousands of dollars a year. And even for patients with established heart disease, insurance companies reject the majority of prescriptions. For a diabetic patient with no prior events? Good luck getting approval.

So VESALIUS-CV gives us the science. But for most patients, hitting these aggressive LDL targets means using cheap, off-patent drugs that are already available — statins and ezetimibe. And until very recently, no one had actually tested whether aiming for a specific lower number made a difference.

Ez-PAVE: The First LDL Target Trial

Consider this case. A 53-year-old woman. Total cholesterol 141. LDL 67. Non-smoker. No family history. Low blood pressure. By every guideline, she was at target.

Four blocked arteries. Open-heart surgery.

Her friend's reaction afterwards: "I thought you only got heart disease if you had high cholesterol." [9]

Her case likely involved other risk factors beyond LDL — but the point stands: an LDL of 67 gave her and her doctor false reassurance.

She's not an isolated case. A study of nearly 137,000 heart attack hospitalisations found that almost 75% of patients had cholesterol levels within recommended targets. Nearly one in five had an LDL below 70 — the supposed goal [10].

So the question becomes: if the target of 70 isn't low enough, what should it be?

That brings us to the second trial presented at ACC 2026. And in some ways, it might be even more important than VESALIUS-CV.

Ez-PAVE is the first randomised controlled trial to directly compare two specific LDL cholesterol targets head-to-head: below 55 mg/dL versus below 70 mg/dL [11].

The trial enrolled 3,048 patients with established cardiovascular disease across 17 centres in South Korea. They were followed for 3 years. Patients were randomised to either the intensive target — LDL below 55 — or the standard target of below 70 [11].

The median LDL achieved was 56 mg/dL in the intensive group and 66 mg/dL in the standard group.

And the results were clear.

The primary composite — cardiovascular death, heart attack, stroke, revascularisation, or hospitalisation for unstable angina — occurred in 6.6% of the intensive group versus 9.7% of the standard group. That's a 33% relative risk reduction. The difference between an LDL of 56 and an LDL of 66 — just 10 mg/dL — translated to a third fewer major events [11].

The individual outcomes were even more striking. Nonfatal heart attacks were more than halved — a hazard ratio of 0.46. Any revascularisation: hazard ratio 0.63 [11].

And what about safety? No signal of harm. No excess diabetes. No myopathy. No liver toxicity [11].

Dr Christopher Cannon, commenting on the trial, put it simply: "55 is our new goal and we need to really embrace that and work hard to get patients to that goal." [12]

All of this aligns with the low target I've personally aimed for for the past few years, based on a study that was a huge wake-up call. Called the PESA study, it imaged the arteries of 4,184 apparently healthy, middle-aged adults with no diagnosed cardiovascular disease.

What they found in a subgroup of those with no conventional cardiovascular risk factors — no high blood pressure, obesity, or insulin resistance — was striking: nearly half already had detectable atherosclerotic plaque somewhere in their vascular system [13].

When they looked at the relationship between LDL levels and plaque burden, the data showed a clear and linear pattern. Plaque still built up even at an LDL of 60, climbing to 64% in those with LDL between 150 and 160. And critically, the authors note that atherosclerosis appears to develop above an LDL threshold of approximately 50 to 60 mg/dL — the very range that the new high-risk guidelines are now targeting [13].

Now, I should note some important limitations. The Ez-PAVE study was conducted entirely in South Korea. We'd want to see this replicated in other populations. And only 60.8% of patients in the intensive arm actually reached the target of below 55 at 3 years [11].

But the implication is powerful. Every point matters. And the old target of 70 leaves significant benefit on the table. The PESA study tells us the same thing.

The Drug Almost Nobody Is Using

Here's the part of this story that frustrates me most as a doctor.

The drug that Ez-PAVE used to help get patients from 66 down to 56 mg/dL wasn't some cutting-edge injectable that costs thousands of dollars a year. It was ezetimibe, used in combination with statins. It's been available since 2002. It's generic. It costs almost nothing. And as of the most recent data, only 6% of patients with established cardiovascular disease are taking it [14].

Six percent.

Karen Aspry, a cardiologist at Brown University, called Ez-PAVE "a real-world approach to how clinicians should be titrating to a lower target using ezetimibe — which many are not doing." [12]

Two-thirds of heart disease patients aren't at their LDL target, despite using statins. There's a cheap generic pill that could help most of them get there. And almost nobody is prescribing it [14].

For my patients, we have an open discussion about aiming for the more aggressive 55 target, rather than 70.

And if you're on a statin but still above target, ask about ezetimibe. It's the lowest-hanging fruit in cardiovascular medicine. Ez-PAVE proved it works. It's been available for over two decades, and it costs little.

For the small group of patients who can't reach target levels even with a statin and ezetimibe, PCSK9 inhibitors remain an option — though insurance access is still a barrier. But there's a reason for optimism here, too. A new oral PCSK9 inhibitor called enlicitide recently showed a 58% LDL reduction in a phase 3 trial. If approved, this could remove the injection barrier entirely [15].

Dr Anand Rohatgi, who helped write the 2026 ACC/AHA guidelines, described it this way: "This guidance reflects a fundamental shift in how we think about cholesterol — not just as a short-term number, but as a lifelong exposure that shapes cardiovascular risk." [16]

Think of it like sun exposure. A single day at the beach probably won't give you skin cancer. But decades of cumulative UV exposure dramatically increases your risk. LDL cholesterol works the same way.

We know this from genetic studies. People who are born with naturally lower LDL — through random variation in genes like PCSK9 — get three times the cardiovascular protection per unit of LDL reduction compared to someone who starts a statin at 50. Same change in cholesterol. Three times the protection. Because the total dose of cholesterol your arteries absorb over a lifetime is what drives risk — not just where your number is today. And that means the earlier you start lowering it, the more protection you accumulate [17].

The effect isn't as strong as medications, but some dietary components have shown effectiveness in lowering cholesterol. Soluble fibre is one of them — and that's why I include psyllium husk, a well-studied source of soluble fibre with cholesterol-lowering effects, in MicroVitamin+ Powder. But just because I take a supplement, that doesn't mean you have to, too.

That woman in Dallas — the aerobics instructor with an LDL of 14 — Helen Hobbs looked at her blood and saw something most scientists would have dismissed. Instead, it launched a twenty-year chain of discoveries. The gene. The drug. The trials. And now, for the first time, head-to-head evidence for the exact number to aim for.

The science is clear. Lower is better. Earlier is better. And the target your doctor was trained on is probably too high.

The only question left is whether we actually act on it.

References

1. https://jamanetwork.com/journals/jama/fullarticle/2847162

2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4607136/

3. https://www.nejm.org/doi/full/10.1056/NEJMoa054013

4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8589637/

5. https://www.jacc.org/doi/10.1016/j.jacc.2012.08.986

6. https://www.nejm.org/doi/full/10.1056/NEJMoa1615664

7. https://www.nejm.org/doi/full/10.1056/NEJMoa2514428

8. https://www.acc.org/About-ACC/Press-Releases/2026/03/28/15/33/Evolocumab-Cuts-Cardiac-Risk-in-Patients-Without-Known-Atherosclerosis-and-With-Diabetes

9. https://www.peoplespharmacy.com/articles/woman-has-heart-attack-despite-very-low-cholesterol

10. https://pubmed.ncbi.nlm.nih.gov/19081406/

11. https://www.nejm.org/doi/full/10.1056/NEJMoa2600283

12. https://www.tctmd.com/news/very-low-ldl-levels-best-secondary-prevention-ez-pave

13. https://www.jacc.org/doi/10.1016/j.jacc.2017.10.024

14. https://pmc.ncbi.nlm.nih.gov/articles/PMC11143858/

15. https://jamanetwork.com/journals/jama/article-abstract/2841258

16. https://www.utsouthwestern.edu/newsroom/articles/year-2026/march-cholesterol-guideline-shifts-focus-earlier-prevention.html

17. https://www.jacc.org/doi/10.1016/j.jacc.2012.09.017